GPR109A (HCAR2) Agonists for Neurodegeneration

GPR109A (HCAR2) Agonists for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GPR109A (HCAR2) Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">Niacin (vitamin B3)</td>
<td>Approved for dyslipidemia</td>
</tr>
<tr>
<td class="label">Butyrate derivatives</td>
<td>Clinical for IBD</td>
</tr>
<tr>
<td class="label">Synthetic agonists</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Target</td>
<td>GPR109A (HCAR2, NIACR1)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>GPCR agonist</td>
</tr>
<tr>
<td class="label">Endogenous Ligands</td>
<td>Butyrate, Niacin, β-hydroxybutyrate</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled</td>
</tr>
</table>

GPR109A, also known as HCAR2 (Hydroxycarboxylic Acid Receptor 2) or NIACR1 (Niacin Receptor 1), is a G-protein coupled receptor that functions as the receptor for butyrate (a short-chain fatty acid produced by gut bacteria) and niacin (vitamin B3). This receptor serves as a critical link between the gut microbiome and brain health, making it an attractive target for neurodegenerative disease therapy. [@wg2020]

GPR109A Biology

GPR109A is encoded by the [HCAR2](/genes/hcar2) gene and is a Gi-protein coupled receptor. Key features include:

GPR109A (HCAR2) Agonists for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GPR109A (HCAR2) Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">Niacin (vitamin B3)</td>
<td>Approved for dyslipidemia</td>
</tr>
<tr>
<td class="label">Butyrate derivatives</td>
<td>Clinical for IBD</td>
</tr>
<tr>
<td class="label">Synthetic agonists</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Target</td>
<td>GPR109A (HCAR2, NIACR1)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>GPCR agonist</td>
</tr>
<tr>
<td class="label">Endogenous Ligands</td>
<td>Butyrate, Niacin, β-hydroxybutyrate</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled</td>
</tr>
</table>

GPR109A, also known as HCAR2 (Hydroxycarboxylic Acid Receptor 2) or NIACR1 (Niacin Receptor 1), is a G-protein coupled receptor that functions as the receptor for butyrate (a short-chain fatty acid produced by gut bacteria) and niacin (vitamin B3). This receptor serves as a critical link between the gut microbiome and brain health, making it an attractive target for neurodegenerative disease therapy. [@wg2020]

GPR109A Biology

GPR109A is encoded by the [HCAR2](/genes/hcar2) gene and is a Gi-protein coupled receptor. Key features include:

• Endogenous Ligands: Butyrate, niacin (vitamin B3), beta-hydroxybutyrate
• Gi-coupled: Inhibits adenylate cyclase, reducing cAMP
• High Expression: Adipose tissue, immune cells (macrophages, neutrophils), brain (microglia, neurons)
• Anti-inflammatory: Activation reduces pro-inflammatory cytokine production

Mechanism of Action

GPR109A agonists work through gut-brain axis modulation and direct neuroprotection:

Key Mechanisms

Therapeutic Potential

Alzheimer's Disease

GPR109A agonists may benefit AD through:

• Reduction of chronic neuroinflammation
• Amyloid plaque modulation
• Support of cognitive function
• Metabolic support via beta-hydroxybutyrate

Parkinson's Disease

GPR109A is particularly relevant for PD:

• High expression in substantia nigra
• Protection of dopaminergic neurons via vagal signaling
• Reduction of gut-derived inflammation
• Potential to modulate alpha-synuclein pathology

Other Applications

• [Multiple Sclerosis](/diseases/multiple-sclerosis)
• Stroke
• Traumatic Brain Injury
• Depression (comorbid with neurodegeneration)

Clinical Development

GPR109A agonists are in various stages of development:

Drug Properties

Side Effects

• Niacin: Flushing, gastrointestinal distress
• Butyrate: Odor, gastrointestinal effects
• Generally well-tolerated at therapeutic doses

References

Related Pages

• [Gut Microbiome Therapy](/therapeutics/gut-microbiome-therapy-neurodegeneration)
• [Microglial Modulation](/therapeutics/microglial-modulation-therapy-neurodegeneration)
• [Ketogenic Diet](/therapeutics/ketogenic-diet-neurodegeneration)
• [HCAR2 Gene](/genes/hcar2)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;